Zoetis (ZTS) Is Back In Focus, Is It Still 23% Below Fair Value?

Why Zoetis is back in focus after a contrarian bet

Michael Burry’s decision to build a position in Zoetis (ZTS) after a steep share pullback has pushed the animal health specialist back onto investor watchlists, particularly among those rethinking crowded AI trades.

Zoetis has been sliding for months, with the share price down 8.23% over the past 30 days and 43.35% year to date, while the 1 year total shareholder return has declined 49.74%. As a result, momentum has clearly faded and recent news around Burry’s interest is landing against a backdrop of heavy selling and reassessment of growth potential.

Scan contrarian ideas, such as Zoetis, that have been sold off significantly but still represent real businesses behind the headlines with the 30 high quality undervalued stocks.

Bulls point to Zoetis as a global animal health leader trading at a steep discount after a harsh reset, while bears see a stalled compounder. Which version does the current valuation actually support?

Most Popular Narrative: 23% Undervalued

Zoetis last traded at $71.33, while the most followed narrative pegs fair value at $92.92, which frames the recent share slide as a valuation reset rather than a verdict on the underlying franchise.

On one hand it’s not a business that’s going to grow much; on the other hand, it’s also not likely to collapse catastrophically. Double-edged sword. The company cites generics as a potential risk in its financial statements. I’m not sure how much of this could be attributable to the 11% YoY decline in Pet segment revenues, but this is just something to watch out for if you’re interested in investing in the business. This article is not meant to replace an exhaustive review of the company, but at first glance the 13x PE does seem to be a fair price for 9-10% EPS growth. And there does appear to be a defensible business behind it.

See why 30 investors see Zoetis as 23% undervalued.

According to ValueInvestingSubstack, this narrative frames Zoetis as a mature animal health business with measured growth, a large companion animal base and a balance sheet that carries meaningful debt after years of buybacks. Earnings quality is described as high, the dividend yield sits at 2.97%, and the DCF work behind the narrative implies that current pricing already bakes in slower revenue expansion of 2.3% per year and earnings growth of 3.5% per year.

The same storyline points out that ZTS is trading well below both the narrative fair value and Simply Wall St’s future cash flow estimate of $202.45, while still showing earnings growth of 1.8% over the past year and 6.9% per year over five years. That mix of modest growth, high reported Return on Equity of 83.77% that is influenced by leverage, and a forecast Return on Equity of 56.5% in three years anchors the view that Zoetis is a slower compounder rather than a high flyer, which may appeal to investors who prefer cash generative businesses over rapid top line expansion.

Result: Fair Value of $92.92 (UNDERVALUED)

Still, Zoetis faces real pressure if US companion animal demand stays weak or if generic competition eats into those high margin blockbuster products.

Find out about the key risks to this Zoetis narrative.

Next Steps

Mixed sentiment around Zoetis does not have to decide your view. Act quickly, review both sides of the story, and weigh the 4 key rewards and 1 important warning sign.

Looking for more Zoetis-like ideas?

If Zoetis has you rethinking where you put fresh capital, do not stop here. Broader opportunity often sits just outside the most talked-about tickers.

• Target reliable cash generators and cut through the noise with a focused view on balance sheet strength and fundamentals using the list of solid balance sheet and fundamentals (23 results).
• Hunt for mispriced opportunities that combine quality and value by scanning the 17 high quality undiscovered gems before others catch on.
• Prioritise resilience in choppy markets and narrow your watchlist to stocks with measured risk profiles through the 30 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com